Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vita Life SciencesASX:VLS 84 Shiller PE Ratio is 18.77 as of Aug. 01, 2026, which is 13% above its 10-year median of 16.67. GuruFocus rates ASX:VLS with a GF Score™ of 84/100 and a GF Value™ of A$2.50 (Fairly Valued). The stock has 1 warning sign investors should review. Among 536 Drug Manufacturers companies, Vita Life Sciences ranks better than 61.01% on this metric.
The historical rank and industry rank for Vita Life Sciences's Shiller PE Ratio or its related term are showing as below:
ASX:VLS'
s Shiller PE Ratio Range Over the Past 10 Years
Min: 7.71 Med: 16.67 Max: 28.89
Current: 19.88
During the past 13 years, Vita Life Sciences's highest Shiller PE Ratio was 28.89. The lowest was 7.71. And the median was 16.67.
ASX:VLS's Shiller PE Ratio is ranked better than 61.01% of 536
companies
in the Drug Manufacturers industry
Industry Median: 24.755
vs ASX:VLS: 19.88
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
Vita Life Sciences's adjusted earnings per share data of for the fiscal year that ended in Dec25 was A$0.184. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is A$0.13 for the trailing ten years ended in Dec25.
Shiller PE for Stocks: The True Measure of Stock Valuation
Vita Life Sciences (ASX:VLS) Shiller PE Ratio Explanation
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Be Aware
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Vita Life Sciences Shiller PE Ratio Related Terms
Vita Life Sciences Shiller PE Ratio Historical Data
* Premium members only.
The historical data trend for Vita Life Sciences's Shiller PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vita Life Sciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vita Life Sciences Shiller PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vita Life Sciences's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Vita Life Sciences's Shiller PE Ratio falls into.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Add all the adjusted EPS together and divide 10 will get our E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Vita Life Sciences (ASX:VLS) has a Shiller PE Ratio of 18.77 as of Aug. 01, 2026. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Vita Life Sciences and its competitors. This is 13% above median its historical median of 16.67. Over the past decade, Vita Life Sciences' Shiller PE Ratio has ranged from 7.71 to 28.89. According to the industry distribution chart, Vita Life Sciences ranks #209 out of 536 companies in the Drug Manufacturers industry, placing it in the top 39%.
Is Vita Life Sciences' Shiller PE Ratio too high?
Vita Life Sciences' current Shiller PE Ratio of 18.77 is 13% above median its 10-year median of 16.67. Over the past 10 years, this metric has ranged from a low of 7.71 to a high of 28.89. The Drug Manufacturers industry median Shiller PE Ratio is 24.76. Vita Life Sciences' value of 18.77 is 24.2% below this industry median. Based on the distribution chart, Vita Life Sciences ranks #209 out of 536 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Vita Life Sciences has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vita Life Sciences' Shiller PE Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vita Life Sciences ranks #209 out of 536 companies for Shiller PE Ratio. This puts Vita Life Sciences in the upper half of its industry. The industry median Shiller PE Ratio is 24.76. Vita Life Sciences' value of 18.77 is 24.2% below this benchmark. Historically, Vita Life Sciences' own Shiller PE Ratio has ranged from 7.71 to 28.89 over the past decade. While the company's 10-year median is 16.67 vs. the industry median of 24.76, Vita Life Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shiller PE Ratio for a Drug Manufacturers company?
The median Shiller PE Ratio among Drug Manufacturers companies is 24.76, based on 536 companies in the industry. Companies in the top quartile (top 25%) have a Shiller PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Shiller PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vita Life Sciences's current Shiller PE Ratio of 18.77 is 24.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shiller PE Ratio mean?
A high Shiller PE Ratio can signal that a stock is expensive relative to its fundamentals. Shiller price-earnings ratio is the ratio of share price to a company's inflation-adjusted earnings over a 10-year period. View historical data on Vita Life Sciences and its competitors. For the Drug Manufacturers industry, the median Shiller PE Ratio is 24.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vita Life Sciences's current Shiller PE Ratio is 18.77, which is 13% above median its own 10-year median of 16.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vita Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Vita Life Sciences (ASX:VLS) is currently considered Fairly Valued. The stock's GF Value™ is A$2.50, compared to a current price of A$2.44 — trading 2.4% below its estimated fair value. The current Shiller PE Ratio is 18.77, which is 13% above median its 10-year median of 16.67 and 24.2% below the Drug Manufacturers industry median of 24.76. Vita Life Sciences' overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shiller PE Ratio calculated?
Shiller PE Ratio is calculated from a company's financial statements. For Vita Life Sciences (ASX:VLS), the current Shiller PE Ratio is 18.77 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vita Life Sciences (ASX:VLS) Overvalued in 2026?
Based on GuruFocus' analysis, Vita Life Sciences stock appears to be undervalued.
The current stock price of A$2.44 is trading 2.4% below its estimated GF Value™ of A$2.50.
GuruFocus considers Vita Life Sciences to be Fairly Valued.
Key valuation signals for ASX:VLS:
Shiller PE Ratio: 18.77 (13% above median its 10-year median of 16.67)
GF Value™: A$2.50 vs. price of A$2.44 (2.4% below fair value)
Industry Position: 24.2% below the Drug Manufacturers median (#209 of 536)
No single metric tells the full story. See the ASX:VLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vita Life Sciences Ltd is an Australian-based pharmaceutical and healthcare company involved in formulating, packaging, selling, and distributing vitamins and supplements. It produces a wide range of premium supplements, vitamins, minerals, herbs, and superfoods catered to all age categories and health conditions. The company markets its products through pharmacies and health food stores under the VitaHealth, VitaScience, and Herbs of Gold brands throughout the Asia-Pacific region. Vita Life Sciences has two operating segments: VMS Operational, which generates maximum revenue, and VMS Investments. Geographically, the Group generates maximum revenue from Malaysia and Singapore, and the rest from Australia, and China and Vietnam.
84GF Score
Get the complete analysis for ASX:VLS
Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VLS has been successfully added to your 
